Sign in

Christopher Hall

Chief Executive Officer and President at Personalis
Board
Since March 2, 2023
Age
56 years
Education
Holds a B.A. in Political Science and Economics from DePauw University and an M.B.A. from Harvard Business School.
Tenure
Joined PSNL in 10-2022 as Senior Vice President and Head of the Diagnostics Business and was promoted to Chief Executive Officer and President in 03-2023.

Also at Personalis

AT
Aaron Tachibana
Chief Financial Officer
RC
Richard Chen
Executive Vice President, Research and Development, and Chief Medical Officer
SM
Stephen Moore
Senior Vice President and Chief Legal Officer

About

Christopher Hall is a seasoned executive with a strong background in the healthcare and diagnostics industry. He completed his education by earning a B.A. in Political Science and Economics from DePauw University and an M.B.A. from Harvard Business School, which laid the foundation for his successful career.

He joined PSNL in October 2022 as the Senior Vice President and Head of the Diagnostics Business and quickly demonstrated leadership abilities that led to his promotion to Chief Executive Officer and President in March 2023.

Prior to his tenure at PSNL, he held high-level positions including CEO at Naring Health, Inc. and multiple leadership roles at Veracyte, Inc., where he played significant roles in driving diagnostic and clinical business growth.

At PSNL, his leadership has been marked by strategic initiatives aimed at expanding partnerships and advancing molecular testing capabilities. His objective approach and extensive experience continue to guide the company's strategic direction.

$PSNL Performance Under Christopher Hall

Past Roles

OrganizationRoleDate RangeDetails
Personalis, Inc. President December 31, 2022 - March 2023 Appointment preceding his CEO promotion
Personalis, Inc. Senior Vice President and Head, Diagnostics Business October 2022 - March 2023 Held prior to becoming CEO
Naring Health, Inc. Chief Executive Officer October 2020 - July 2022 Medical research services company
Veracyte, Inc. President, Chief Operating Officer, and Chief Commercial Officer February 2010 - July 2019 Global diagnostics company

Fixed Compensation

Data from  FY 2024
Component NameAmountPayment ScheduleAdditional Details
Salary $600,000Annual (2024)Base salary for 2024 with a 9.1% increase from 2023
Service-Based Option Awards 400,000 shares36 successive equal monthly installments beginning March 15, 2024Vesting subject to continued service
401(k) Matching Contributions $3,000Contributed during fiscal 2024Matching contribution under the company’s 401(k) plan

Performance Compensation

Data from  FY 2024

Performance-Based Option Awards (2024)

MetricValueDetails
Grant Date February 2024Options granted in February 2024
Number of Shares 100,000 sharesPerformance-based stock options
Exercise Price $1.61 per shareOption exercise price
Grant Date Fair Value $0.3 millionTotal fair value of the grant
Vesting Schedule 0%-100% based on achievementVests upon reaching Medicare reimbursement milestones by December 31, 2025, with continuous service required
Grant Date Stock Price N/ASpecific stock price not provided

Non-Equity Incentive Plan Compensation (2024)

MetricValueDetails
Bonus Target $540,000Set at 90% of the base salary of $600,000
Actual Bonus Earned $423,000Achieved 80% of the bonus target due to 80% of company goals met
Performance Metrics Weights Revenue: 60%, Expense Reduction: 10%, Publication Submissions: 10%, Medicare Coverage Submissions: 10%, CTA Agreement: 10%Goals based on pre-established company targets
Evaluation Period 2024 (with submissions by Q3 and December 31, 2024)Includes milestones on revenue, expense, academic submissions, Medicare coverage, and CTA agreement
Conditions Continued service requiredBonus payout contingent on continued service through payment date